Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P30536 (PBS)
 9,886 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Despite aggressive treatment, early onset neonatal Listeria monocytogenes infection continues to have high morbidity and mortality. We recently showed that pretreatment of newborn L. monocytogenes-infected rats with interferon (IFN)-alpha/beta or recombinant rat IFN-gamma dramatically improves survival. However, in the present experiment, when newborn rats were treated with IFN-alpha/beta or recombinant rat IFN-gamma after intraperitoneal injection with Listeria there was no benefit. Because most deaths occurred at or before 3 d in this animal model, we reasoned that the effect of interferon may be evident if animals survived longer. To accomplish this and test this hypothesis, ampicillin (20 mg/kg/d) was given 48 h after bacterial challenge. When ampicillin-treated Listeria-infected rats were randomized to receive PBS, IFN-alpha/beta, or recombinant rat IFN-gamma, mortality rates were 79, 76, and 69%, respectively (p greater than 0.05 versus PBS). Animals treated in a similar fashion after a lower bacterial inoculum (25% lethal dose) were killed 5 d after bacterial challenge. Bacterial concentrations in the spleen were higher for IFN-treated animals than controls. We conclude that no direct benefit of IFN is found if it is given after bacterial infection has been established.
 ...
PMID:Neonatal Listeria monocytogenes infection is refractory to interferon. 171 35

Peritoneal macrophages from CBA mice incubated with rIFN-gamma are effective in killing the protozoal parasite Leishmania major in vitro. This leishmanicidal activity can be completely inhibited by L-NG-monomethyl arginine (L-NMMA), a specific inhibitor of the L-arginine:nitric oxide (NO) pathway. The culture supernatants of macrophage activated by IFN-gamma contain increased levels of NO2-, the production of which is inhibited by L-NMMA, but not by its D-enantiomer. L. major promastigotes are killed when incubated at room temperature in PBS containing NO. These data demonstrate that NO is an effector mechanism in macrophage killing of intracellular protozoa. The importance of NO in vivo is demonstrated by the finding that CBA mice infected with L. major developed exacerbated disease when L-NMMA was injected into the lesions, resulting in 10(4)-fold increases in the number of parasites extractable from the lesions.
 ...
PMID:Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. 235 28

The present study was initiated to study the efficacy of donor pretreatment with interferon-gamma to induce class II antigen expression in heart tissue, and to investigate whether this pretreatment would influence heart allograft survival. BN rats were used as donors, and LEW rats as recipients. During a period of 3 consecutive days prior to transplantation, IFN-gamma was administered to BN rats via continuous intravenous infusion at dosages of 10(3), 10(4), and 5.10(4) U/hr. Control animals were infused with PBS; each group consisted of 9 animals. Analysis of IFN-gamma induced class II expression by immunoperoxidase staining revealed a significant, fourfold increase in the number of dendriticlike cells, irrespective of the IFN-gamma dose given (controls: 15 +/- 4 vs. highest dose group: 57 +/- 9 cells/mm2; P less than 0.005). Endothelial cells of arteries and venules remained class II antigen negative. Grafting of hearts from IFN-gamma perfused donors to untreated recipients (6 animals per group), did not result in a shortened or prolonged survival time in any of the experimental groups, as compared to controls. These results indicate that upgrading of class II antigen expression on dendriticlike cells is not likely to be of importance for the process of rejection.
 ...
PMID:Increase of major histocompatibility complex class II--positive cells in cardiac allografts by interferon-gamma has no impact on graft survival. 251 99

The (NZB X NZW)F1 mouse is recognized as an important animal model of the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F1 mice were treated either with IFN-gamma or with PBS. The results demonstrate that IFN-treated animals have accelerated development of fatal immune complex glomerulonephritis relative to age-matched controls. On the other hand, administration of mAbs specific for IFN-gamma to such mice from 4 to 7 mo of age resulted in significant remission. Development of both proteinuria and anti-DNA antibodies were delayed and survival at 11 mo was increased from less than 20% to 95% in treated mice relative to controls (p less than or equal to 0.001). These findings may have therapeutic implications for the treatment of SLE.
 ...
PMID:In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. 311 9

Protein antigens elicit humoral responses in mice that consist predominantly of IgG1 antibodies. We have now investigated the ability of IL-12, a cytokine reported to augment IgG2a anti-hapten responses through activation of Th1 cells, to alter antibody responses to hen eggwhite lysozyme (HEL). The normal response of BALB/c mice to HEL is highly restricted to IgG1 expression and therefore provides an excellent system for determining effects of cytokines on expression of other isotypes. Seven days after immunization, IL-12 treated mice demonstrated greatly elevated HEL-specific IgG2a antibody levels and suppressed IgG1 production, while PBS-treated control mice showed a typical IgG1-restricted response. On day 28, IL-12-treated mice showed heightened serum antibody levels of both isotypes. Delaying cytokine treatment until after the typical IgG1 anti-HEL response had already been established also led to significant elevation of serum IgG2a antibody levels. These effects correlated with increased IFN-gamma production; however, administration of IL-12 plus anti-IFN-gamma had little influence on IgG2a enhancement, although it did relieve the early IgG1 suppression. Furthermore, the differential effects of Il-12 on isotype expression did not correlate with time; in fact, IgG2a enhancement correlated with loss of IgG1 suppression. Our findings indicate that (i) IL-12 reproducibly induces large amounts of IgG2a HEL-specific antibodies in vivo; (ii) it can alter isotype profiles of both primary and secondary responses; and (iii) its effects on humoral immunity are not completely explained by induction of Th1 cell derived IFN-gamma.
 ...
PMID:Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. 749 60

Cytokines play a major role in promoting naive Th cells to differentiate into Th1 or Th2 cells. While IL-4 is recognized as the primary pro-Th2 inducing cytokine, the identity of its cellular sources during the development of a Th2 response remains unclear. We have used Schistosoma mansoni eggs, potent stimulators of Th2 responses both during the natural progression of murine schistosomiasis and when experimentally isolated and injected into normal mice, to examine IL-4 production early in the evolution of an Ag-driven Th2 response. Analysis of peritoneal exudate cells by IL-4 specific reverse transcriptase-PCR and ELISPOT, at times following i.p. egg injection in naive C57BL/6 mice, revealed a marked, transient elevation in IL-4 production at 2 to 12 h after Ag exposure. This response was temporally accompanied by eosinophil and neutrophil infiltration and mast cell disappearance. The pattern of early IL-4 production and peritoneal cell infiltration was observed in egg-injected CD4+ cell-depleted and nude C57BL/6 mice, strongly suggesting that a non-T cell is the source of early IL-4 and that the stimulus leading to the egg-induced changes in cellular composition are T cell independent. In addition to IL-4 transcripts, peritoneal exudate cells from egg-injected T cell replete or deficient mice contained IFN-gamma and IL-12 transcripts. Control i.p. PBS injections led to no or minimal cytokine gene transcription. Early IL-4 was predictive of subsequent Th2 response development since, in contrast to C57BL/6 mice, egg-injected BALB/c mice demonstrated no detectable IL-4 production at 12 h and mounted a comparatively weak egg Ag-specific Th2 response.
 ...
PMID:Early IL-4 production by non-CD4+ cells at the site of antigen deposition predicts the development of a T helper 2 cell response to Schistosoma mansoni eggs. 759 87

The immunologic and histologic changes associated with lung allograft rejection are believed to result from the presentation of donor lung alloantigens to recipient lymphocytes resulting in up-regulated Th1 lymphocyte activity. The ability of allogeneic lung immune cells to induce the pathologic and immunologic changes associated with acute lung allograft rejection are unknown. The current study determined whether allogeneic (C57BL/6, I-a(b)) bronchoalveolar lavage (BAL) cells (> or = 97% macrophages), when instilled into the lungs of recipient BALB/c mice (I-a(d)), induced the histology and immunology associated with acute lung allograft rejection. BALB/c mice received BAL cells from either C57BL/6 mice (allogeneic instillate) or BALB/c mice (autologous instillate) or PBS (control) by nasal insufflation weekly for 4 wk. Allogeneic BAL cells resulted in a lymphocytic bronchitis and vasculitis analogous to grade 1 to 2 lung allograft rejection. The mice given allogeneic instillates had a greater percentage of lymphocytes in the BAL fluid than those given autologous instillates. After instillation of allogeneic BAL cells, the Th1 cytokines, IL-2 and IFN-gamma (IFN-gamma), were produced locally in greater quantities and more frequently than Th2 cytokine IL-10. IL-4, another Th2 cytokine, was not detected. The local production of IgG1 and IgG2a, which are dependent on IL-4 and IFN-gamma, respectively, were increased. However, only IgG2a was deposited in the perivascular and peribronchiolar tissues. These data show that installation of allogeneic BAL cells into the airways of recipient mice induced up-regulated Th1 lymphocyte activity and caused the histologic changes associated with lung allograft rejection.
 ...
PMID:Allogeneic bronchoalveolar lavage cells induce the histology of acute lung allograft rejection, and deposition of IgG2a in recipient murine lungs. 765 Apr 3

Recently, an immunocompetent in vivo mouse model was developed based on germ cell alkaline phosphatase (GCAP) transgenic (FVB/N x C3H) mice in which both placental alkaline phosphatase (PLAP)+ and GCAP+ solid MO4 tumors develop. A bispecific anti-PLAP/GCAP anti-mouse CD3 antibody (Ab) 7E8 x 7D6, previously shown to induce efficient dose-dependent T-cell proliferation and PLAP+ tumor cell lysis in the presence of recombinant IL-2 and the anti-mouse CD3 Ab 7D6, was used in this report in in vivo lysis experiments targeting GCAP+ tumors grown in GCAP+ transgenic mice. Mice received injections i.v. twice a week with PBS (group 1) or with 10 micrograms of the bispecific Ab 7E8 x 7D6, either alone (group 2) or combined with 1 microgram of the anti-CD3 Ab 7D6 (group 3), starting 7 days after the tumor inoculation. A fourth group received a local treatment with mouse splenocytes precoated with 10 micrograms 7E8 x 7D6 and 1 microgram 7D6. In between Ab injections, groups 2, 3, and 4 received 10(4) units recombinant IL-2 (i.v.) every day. Two weeks of treatment with the bispecific Ab either alone or combined with 7D6 resulted in a significant decrease of GCAP+ tumor cells in groups 2 and 3 (4 +/- 3% and 10 +/- 11% GCAP+ cells/tumor) as compared to the nontreated tumors (95 +/- 5% GCAP+ cells), although tumor volumes were not significantly different (12 +/- 15 cm3 and 14 +/- 11 cm3 versus 16 +/- 7 cm3). Apparently, the elimination of GCAP+ cells from the tumor seemed to favor conditions enabling the outgrowth of the few GCAP- cells originally present in the tumor inoculate. In contrast, tumor volumes in group 4 (local treatment) were significantly smaller (P < 0.03; 5 +/- 10 cm3, 8 +/- 11% GCAP+ cells) as compared to the nontreated group, probably due to the presence of higher amounts of Ab and infiltrated activated T cells (567 +/- 322 CD5+ cells/mm2) capable of secreting cytostatic cytokines like tumor necrosis factor alpha and IFN-gamma as compared to groups 2 and 3 (266 +/- 135 and 198 +/- 86 CD5+ cells/mm2, respectively). In summary, this study clearly demonstrated that bispecific antibodies specifically concentrate cytotoxic T cells into a solid tumor in vivo, with subsequent elimination of the targeted tumor cell.
 ...
PMID:Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice. 767 Dec 51

AKR/J mice, highly susceptible to spontaneous T cell leukemogenesis, were protected from developing the disease by H-2-compatible allogenic bone marrow transplantation (BMT) and intermittent treatment with interleukin-2(IL-2). Allogeneic BMT from C3H/HeJ mice and treatment with PBS yielded T cell leukemia in chimeras after the same latent period as that observed in normal AKR/J mice. In contrast, IL-2-treated chimeras caused an incidence of only 40% T cell leukemia. The preventing effect of IL-2 on leukemia development was not observed in one-year-treated chimeras, probably due to a lack of continuous antileukemic effects over the long term. Both LAK and NK activities in spleen cells were significantly increased in IL-2-treated chimeras. The cytotoxicity against T cell lymphoma cell line derived from AKR/J also increased in the IL-2-treated chimeras. Similarly, LPS-, PWM-, and IL-2-induced responses were increased in the IL-2-treated chimeras. TNF-alpha secretion from spleen cells also rose after IL-2-administration. IL-1 beta, IFN-gamma, and TNF-alpha mRNA became detectable in spleen cells using the PCR technique. The characteristics of leukemia cells in chimeras with overt leukemia were not directly affected by IL-2 administration. It is suggested that partial inhibition of spontaneous T cell leukemia development in AKR/J mice by allogeneic BMT and IL-2 may be due to the enhancement of graft-versus-leukemia effects. Further study may provide insights into the mechanisms involved in preventing leukemia development after allogenic BMT and IL-2 in AKR/J mice.
 ...
PMID:Antileukemic effect of interleukin-2 on spontaneous development of leukemia after H-2-compatible allogenic bone marrow transplantation in AKR/J mice. 792 84

A protein purified from Leishmania donovani promastigotes, dp72, was shown to partially protect BALB/c mice against a challenge by this parasite. Immunized mice infected i.v. with 10(7) L. donovani promastigotes showed a 0, 60, and 78% reduction in liver parasite burden compared with the control mice at each time point examined after challenge, 1, 20, and 108 days, respectively. Western blotting demonstrated that the sera from the immune mice, which reacted specifically with dp72 in lysates of L. donovani, cross-reacted with one major band in total homogenates of Leishmania major and Leptomonas collosoma. Lymphocyte proliferation to crude and pure parasite Ag was also examined in mice immunized with dp72. Strong proliferation was found at low concentrations of crude L. donovani Ag (0.5 micrograms/ml) and with pure dp72. Proliferation at higher concentrations to crude L. major and L. collosoma Ag was observed. Little or no reaction (stimulation index < 1.0) was seen with other pure leishmanial Ag, including gp70-2, the promastigote surface protease, and lipophosphoglycan. Depletion in vitro of the CD4+ T cell subset from immune spleen cells abolished proliferation to dp72, whereas depletion of CD8+ T cells enhanced proliferation to the pure Ag. Experiments in vivo showed that immunized mice treated with antibodies to either CD4+, CD8+, both T cell subsets, or to IFN-gamma had larger LPB (178, 173, 176, and 130%, respectively) after challenge with L. donovani than nonimmunized controls. Mice immunized with dp72 but treated with either PBS or mouse Ig showed reduced LPB, 81 and 61%, respectively, compared with the nonimmunized animals. BALB/c mice immunized with dp72 were also protected against L. major which causes cutaneous leishmaniasis. Immunized mice infected with either 10(4) or 10(6) promastigotes did not develop lesions. Limiting dilution assays confirmed the protection.
 ...
PMID:Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. 845 Feb 15


1 2 3 4 5 6 7 8 9 10 Next >>